Top

Published in:

01-01-2021 | Lymphoma | Original Paper

Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma

Authors: Sahar K. Hegazy, Sahar M. El-Haggar, Suzan A. Alhassanin, Eman I. El-berri

Published in: Medical Oncology | Issue 1/2021

Abstract

The development of drug resistance remains the major obstacle to clinical efficacy of cancer chemotherapy. Consequently, finding new therapeutic options for cancerous patients is an urgent need. Sixty newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients were recruited from Clinical Oncology Department, Faculty of Medicine, Menoufia University, Egypt prospectively randomized to three groups (n = 20 for each group). Group one (control group) received R-CHOP standard chemotherapy {Rituximab, Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin)®, Vincristine (oncovin)®, prednisolone in the first five days of cycle}, group two received lansoprazole (LAN) 60 mg p.o. bid for only one week before starting each of cycle + R-CHOP and group three received famotidine (FAM) 40 mg p.o. once daily one week before cycle and continues daily through the cycle + R-CHOP for six cycles. Blood samples were obtained for biochemical analysis of transforming growth factor-β (TGF-β), Basic fibroblast growth factor (bFGF), interleukin-9 (IL-9), nuclear factor-kappa B (NF-κB) and Caspase 3 before and after six cycles of therapy. The obtained data showed that LAN and FAM resulted in significant decrease in (LDH, TGF-β, bFGF and IL-9, respectively) and significant increase in (Caspase-3). In addition, LAN produced a significant elevation in the response rate compared to the control group or the FAM group. Both LAN and FAM as adjuvant therapy represents a promising anticancer strategy in DLBCL by modulation of malignancy homeostasis mechanisms and boosting chemotherapy antitumor effects without further toxicity. In addition, LAN has a synergetic effect in improving the response rate.

Trial registration Clinical Trial.gov Identifier: NCT0364707.

Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Abdel-Hamid M, Fahmy A, et al. Case-control study of non-Hodgkin’s lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol. 2004;33:1034–9. https://doi.org/10.1093/ije/dyh183.CrossRefPubMed

Jurisić V, Plećić M, Colović N, Čemerikić-Martinović V, Janković M, Čolović M. MUM-1 and bcl-2 Positive Primary Diffuse Large B Cell Non-Hodgkin’s Lymphoma of the Colon. Arch Iran Med. 2016;19:297–9.PubMed

Coiffier B, Sarkozy C. Diffuse large B cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016:366–78. https://doi.org/10.1182/asheducation-2016.1.366.CrossRefPubMedPubMedCentral

Jurišić V, Vuletić A, Martinović K, Konjević G. The role of NK cells in cancer. In: Rezaei N, editor. Cancer immunology. Cham: Springer; 2020. https://doi.org/10.1007/978-3-030-30845-2_9.CrossRef

Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. mAbs. 2009;1:222–9. https://doi.org/10.4161/mabs.1.3.8292.CrossRefPubMedPubMedCentral

Jiang J, Liu Y, Tang Y, Li L, Zeng R, Zeng S, Zhong M. ALDH1A1 induces resistance to CHOP in diffuse large B cell lymphoma through activation of the JAK2/STAT3 pathway. Onco Targets Ther. 2016;9:5349–60. https://doi.org/10.2147/OTT.S107957.CrossRefPubMedPubMedCentral

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The repurposing drugs in oncology (ReDO) project. Ecancermedicalscience. 2014;8:442. https://doi.org/10.3332/ecancer.2014.442.CrossRefPubMedPubMedCentral

Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol. 2017;43:74–89. https://doi.org/10.1016/j.semcancer.2017.03.001.CrossRefPubMed

10.

Stransky L, Cotter K, Forgac M. The function of V-ATPases in cancer. Physiol Rev. 2016;96:1071–91. https://doi.org/10.1152/physrev.00035.2015.CrossRefPubMedPubMedCentral

11.

Fais S. Evidence-based support for the use of proton pump inhibitors in cancer therapy. J Transl Med. 2015;13:368. https://doi.org/10.1186/s12967-015-0735-2.CrossRefPubMedPubMedCentral

12.

Ikemura K, Hiramatsu S, Okuda M. Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy. Front Pharmacol. 2017;8:911. https://doi.org/10.3389/fphar.2017.00911.CrossRefPubMedPubMedCentral

13.

Wang BY, Zhang J, Wang JL, Sun S, Wang ZH, Wang LP, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:2–12. https://doi.org/10.1186/s13046-015-0194-x.CrossRef

14.

Marchetti P, Milano A, D’Antonio C, Romiti A, Falcone R, Roberto M, et al. Association between proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumors: a Randomized Phase II Trial. Clin Colorectal Cancer. 2016;15:377–80. https://doi.org/10.1016/j.clcc.2016.06.005.CrossRefPubMed

15.

Shim YK, Kim N. The effect of H₂ receptor antagonist in acid inhibition and its clinical efficacy. Korean J Gastroenterol. 2017;70:4–12. https://doi.org/10.4166/kjg.2017.70.1.4.CrossRefPubMed

16.

Faustino-Rocha AI, Ferreira R, Gama A, Oliveira PA, Ginja M. Antihistamines as promising drugs in cancer therapy. Life Sci. 2017;172:27–41. https://doi.org/10.1016/j.lfs.2016.12.008.CrossRefPubMed

17.

Vila-Leahey A, Oldford SA, Marignani PA, Wang J, Haidl ID, Marshall JS. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016;5:e1151591. https://doi.org/10.1080/2162402X.2016.1151591.CrossRefPubMedPubMedCentral

18.

Abdul-Hussein M, Freeman J, Castell D. Concomitant administration of a histamine 2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression. Pharmacotherapy. 2015;35:1124–9. https://doi.org/10.1002/phar.1665.CrossRefPubMed

19.

Zhang S, Wang Y, Li SJ. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun. 2014;448:424–9. https://doi.org/10.1016/j.bbrc.2014.04.127.CrossRefPubMed

20.

Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–13. https://doi.org/10.1093/jnci/djh305.CrossRefPubMed

21.

De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, et al. pH dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127:207–19. https://doi.org/10.1002/ijc.25009.CrossRefPubMed

22.

Cataldi M, Borriello F, Granata F, Annunziato L, Marone G. Histamine receptors and antihistamines: from discovery to clinical applications. Chem Immunol Allergy. 2014;100:214–26. https://doi.org/10.1159/000358740.CrossRefPubMed

23.

Parshad R, Kapoor S, Gupta SD, Kumar A, Chattopadhyaya TK. Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol. 2002;41:362–5. https://doi.org/10.1080/028418602760169415.CrossRefPubMed

24.

Jurisic V, Konjevic G, Banicevic B, Djuricic B, Spuzic I. Different alterations in lactate dehydrogenase (LDH) activity and profile of peripheral blood mononuclear cells in Hodgkin’s and non-Hodgkin’s lymphomas. Eur J Haematol. 2000;64:259–66. https://doi.org/10.1034/j.1600-0609.2000.90117.x.CrossRefPubMed

25.

Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:115–24. https://doi.org/10.1007/978-94-017-7215-0_8.CrossRefPubMed

26.

William BM, Bongu NR, Bast M, Bociek RG, Bierman PJ, Vose JM, Armitage JO. The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter. 2013;35:189–91. https://doi.org/10.5581/1516-8484.20130055.CrossRefPubMedPubMedCentral

27.

El-Hefnia A, Alazzazib N, Abu Taleb F. Prognostic utility of transforming growth factor beta-1 in diffuse large cell non-hodgkin lymphoma. J Hematol. 2015;4:131–6. https://doi.org/10.14740/jh194w.CrossRef

28.

Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, et al. Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin’s lymphoma. Br J Cancer. 2002;86:1770–5. https://doi.org/10.1038/sj.bjc.6600330.CrossRefPubMedPubMedCentral

29.

Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015;13:249. https://doi.org/10.1186/s12967-015-0614-x.CrossRefPubMedPubMedCentral

30.

Nelson C, Lee J, Ko K, Sikora AG, Bonnen MD, Enkhbaatar P, et al. Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model. Front Pharmacol. 2017;8:16. https://doi.org/10.3389/fphar.2017.00016.CrossRefPubMedPubMedCentral

31.

Rivoltini L. Tumor-induced dysfunctions in adaptive and innate immunity: a novel therapeutic target for melanoma patients? Keio J Med. 2011;60

32.

Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho SW, et al. Selective induction of with proton pump inhibitor in gastric apoptosis cancer cells. Clin Cancer Res. 2004;10:8687–96. https://doi.org/10.1158/1078-0432.CCR-04-1065.CrossRefPubMed

33.

Ji L, Wang T, Tian L, Song H, Gao M. Roxatidine inhibits fibrosis by inhibiting NF-κB and MAPK signaling in macrophages sensing breast implant surface materials. Mol Med Rep. 2020;21:161–72. https://doi.org/10.3892/mmr.2019.10815.CrossRefPubMed

34.

Mandegari A, Gholami-Javadie A, Jafari M, Sabouri S. Synergistic therapeutic effects of cimetidine/famotidine in combination with doxorubicin on cancer cell lines. J Mazandaran Univ Med Sci. 2019;28:180–5.

35.

Lv X, Feng L, Fang X, Jiang Y, Wang X. Overexpression of IL-9 receptor in diffuse large B cell lymphoma. Int J Clin Exp Pathol. 2013;6:911–6.PubMedPubMedCentral

36.

El Halawani N, El Sordi M, Aiad M, El Sabaa B, Hashim A. Diagnostic and prognostic value of nuclear factor kappa-B in diffuse large B cell lymphoma in Egyptian patients with hepatitis C virus genotype 4. Am J Mol Biol. 2019;9:121–43. https://doi.org/10.4236/ajmb.2019.93010.CrossRef

37.

Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–7. https://doi.org/10.1007/s10620-009-0951-9.CrossRefPubMedPubMedCentral

38.

Geeviman K, Babu D, Prakash BP. Pantoprazole induces mitochondrial apoptosis and attenuates NF-κB signaling in glioma cells. Cell Mol Neurobiol. 2018;38:1491–504. https://doi.org/10.1007/s10571-018-0623-4.CrossRefPubMed

39.

Balza E, Piccioli P, Carta S, Lavieri R, Gattorno M, Semino C, et al. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death Dis. 2016;7:e2304. https://doi.org/10.1038/cddis.2016.218.CrossRefPubMedPubMedCentral

40.

Feng LL, Gao JM, Li PP, Wang X. IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B cell non-hodgkin’s lymphoma. J Clin Immunol. 2011;31:1084–94. https://doi.org/10.1007/s10875-011-9584-9.CrossRefPubMed

41.

Elsawy WH, Abdel Kader M, Elfar A, Gharib A, Eltrhony S, Dorgham Y. Prognostic implications of caspase-3 expression in patients with diffuse large B cell lymphoma (DLBCL). J Clin Oncol. 2006;24:17500. https://doi.org/10.1200/jco.2006.24.18_suppl.17500.CrossRef

42.

Yeo M, Kim DK, Park HJ, Cho SW, Cheong JY, Lee KJ. Retraction: blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer. Cancer Sci. 2008;99:185. https://doi.org/10.1111/j.1349-7006.2007.00642.x.CrossRefPubMed

43.

Yeo M, Kim DK, Han SU, Lee JE, Kim YB, Cho YK, et al. Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut. 2006;55:26–33. https://doi.org/10.1136/gut.2005.067454.CrossRefPubMedPubMedCentral

44.

Shen Y, Chen M, Huang S, Zou X. Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2. Oncol Lett. 2016;11(1):717–22. https://doi.org/10.3892/ol.2015.3912.CrossRefPubMed

45.

Vard N, köroglu E, Tüzün S, Dolapçıoğlu C, Dabak R, . Comparison of the efficacies of proton pump inhibitors and H₂ receptor antagonists in on-demand treatment of gastroesophageal reflux disease. Anatol JFM. 2018;1:8–12. https://doi.org/10.5505/anatoljfm.2018.87597.CrossRef

Title: Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma
Authors: Sahar K. Hegazy
Sahar M. El-Haggar
Suzan A. Alhassanin
Eman I. El-berri
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Lymphoma
Famotidine
Lansoprazole
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Medical Oncology / Issue 1/2021
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-020-01452-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Steps in metastasis: an updated review

Bioinformatic analysis of dysregulated proteins in prostate cancer patients reveals putative urinary biomarkers and key biological pathways

Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review

Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor

Short-term effects of a Paleolithic lifestyle intervention in breast cancer patients undergoing radiotherapy: a pilot and feasibility study

LDLRAD2 promotes pancreatic cancer progression through Akt/mTOR signaling pathway

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page